Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Shares Outstanding for 7 consecutive years, with $66.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 23.37% to $66.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.6 million, a 23.37% increase, with the full-year FY2025 number at $66.6 million, up 23.37% from a year prior.
  • Shares Outstanding was $66.6 million for Q4 2025 at Fulcrum Therapeutics, up from $54.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $66.6 million in Q4 2025 to a low of $21.0 in Q2 2021.
  • A 5-year average of $50.4 million and a median of $54.0 million in 2024 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 100.0% in 2021, then surged 195277066.67% in 2022.
  • Fulcrum Therapeutics' Shares Outstanding stood at $40.6 million in 2021, then increased by 28.24% to $52.1 million in 2022, then increased by 18.84% to $61.9 million in 2023, then fell by 12.84% to $54.0 million in 2024, then increased by 23.37% to $66.6 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Shares Outstanding are $66.6 million (Q4 2025), $54.1 million (Q3 2025), and $54.1 million (Q2 2025).